Mahkam Zanganeh bought $10k of SMMT
Chief Executive Officer at Summit Therapeutics Inc.. 5,000 shares at an average of $2.07, traded Dec 12, 2023, filed Dec 13, 2023.
Score components
- +25RoleCEO
- 0Trade size$10k at market
- 0Relative to holdingsHoldings up 1.0%
- +8Price context59% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (2 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +32.5%, 3m +92.7%, 6m +252.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001599298-23-000103, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2023 | XIn-the-money exercise Common Stock | +489,814 | $1.44 | $705k | 489,814 | Dec 13, 2023 |
| Dec 12, 2023 | POpen-market purchase Common Stock | +5,000 | $2.07 | $10k | 494,814 | Dec 13, 2023 |
| Dec 11, 2023 | XIn-the-money exercise Common Stockindirect: By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | +315,681 | $1.58 | $499k | 24,889,479 | Dec 13, 2023 |
| Dec 11, 2023 | XIn-the-money exercise Warrant (right to buy)derivative | -489,814 | $0.00 | $0 | 0 | Dec 13, 2023 |
| Dec 11, 2023 | XIn-the-money exercise Warrant (right to buy)derivativeindirect: By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | -315,681 | $0.00 | $0 | 0 | Dec 13, 2023 |
Related signals
Other insiders at Summit Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 78Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $50M 3,810,000 shares | +1% | |
| 83Strong | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $50M 3,810,000 shares | +1% | |
| 73Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $1.5M 100,000 shares | +0% | |
| 76Notable | Summit Therapeutics Inc. | Manmeet Singh Soni COO and CFO | $722k 50,000 shares | +2% | |
| 78Notable | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $1.5M 100,000 shares | +0% | |
| 73Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $500k 26,680 shares | +53% | |
| 73Notable | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $500k 26,680 shares | +53% | |
| 55Moderate | Summit Therapeutics Inc. | Yu Xia director | $10.0M 533,617 shares | +2% | |
| 53Moderate | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $6.0M 338,394 shares | +0% | |
| 53Moderate | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $6.0M 338,394 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.